Compare Novartis AG (NVS) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.66. The key difference: Novartis AG pays a 3.02% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Novartis AG is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| NVS | QDTE | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $36.60 |
52-Week Low | $119.31 | $26.85 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
QDTE trades at $29.69 with a 1.19% daily gain, but technical indicators signal bearish momentum with resistance at $30. The ETF faces fundamental concerns as its high distribution yield appears funded by return of capital rather than organic earnings, potentially eroding NAV over time. Recent news highlights growing skepticism about the sustainability of its 24% yield strategy.
Outlook remains cautious due to structural yield concerns and NAV erosion risks. While weekly distributions attract income seekers, the fund's reliance on return of capital poses significant long-term value destruction risks. Investors should weigh high current income against potential principal erosion in volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
